Biomaterials-based metabolic rescue of dendritic cells for vaccine design
基于生物材料的树突状细胞代谢拯救用于疫苗设计
基本信息
- 批准号:10543178
- 负责人:
- 金额:$ 32.28万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-01 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAdoptive TransferAntigen-Presenting CellsAntigensBRAF geneBiocompatible MaterialsBiological AssayBone MarrowCD8-Positive T-LymphocytesCD8B1 geneCancer VaccinesCarbonCellsCitric Acid CycleCollecting CellCombination immunotherapyComplexContralateralCytotoxic T-LymphocytesDataDendritic CellsDendritic cell activationDevelopmentDopachrome isomeraseDoseFormulationFrequenciesFructoseFutureGATA3 geneGenerationsGenus HippocampusGlutaminaseGlycolysisGlycolysis InhibitionGlycolysis PathwayGoalsGrowthHelper-Inducer T-LymphocyteHumanImmuneImmunocompetentImmunohistochemistryImmunotherapyIn VitroIntravenousKidneyKineticsLiverLysineMacrophageMalignant NeoplasmsMalignant neoplasm of ovaryMaximum Tolerated DoseMeasuresMetabolicMetabolic PathwayMetabolismMissionMitochondriaModelingMusNF-kappa BOrganOxygen ConsumptionPathway interactionsPeptidesPhagocytosisPoly I-CPolymersProductionProliferatingPublic HealthPublishingReactionReactive Oxygen SpeciesResearchResearch Project GrantsRespirationRoleSafetySortingStress TestsSuccinatesT cell responseT memory cellT-LymphocyteTechnologyTestingToxic effectTreatment ProtocolsTumor BurdenTumor-Infiltrating LymphocytesTumor-infiltrating immune cellsUnited States National Institutes of HealthVaccine DesignVaccine TherapyVaccinesVertebral columnWorkappropriate dosecancer cellcancer typecytotoxicdraining lymph nodeethylene glycolexhaustexperimental studyextracellularin vivoinhibitorinorganic phosphatelong term memorylymph nodesmelanomametabolic fitnessmitochondrial fitnessmouse modelmutantnanoparticleneoplasm immunotherapynovelparticlepreventprogrammed cell death protein 1programsresponsescale upsubcutaneoustumortumor growthtumor microenvironmentvaccine efficacyvaccine response
项目摘要
Abstract
The main goal of this proposal is to develop biomaterial-based technologies that can modulate the functions of
DCs and T-cells in the draining lymph nodes in the presence of systemically delivered metabolic inhibitors. The
hypothesis of this proposal is that polymeric biomaterials-based particles generated from central-carbon
metabolites (targeting DCs via phagocytosis) can restart glycolysis/TCA cycle in DCs in the presence of
metabolic inhibitors and will also induce robust vaccine responses in immunocompetent mice. Notably, we
have generated polymers of central-carbon metabolites from glycolysis and TCA cycle, which were able to
activate DCs even in the presence of metabolic inhibitors. Moreover, these particles were able to rescue the
metabolic inhibition, as observed by up-regulated extracellular acidification rate (ECAR) and oxygen
consumption rate (OCR) in bone marrow derived DCs. In vivo PEGS particle formulations delivering TRP-2
peptide (without any adjuvant), were able to prevent the growth of subcutaneous B16F10 tumors in the
presence of CB-839 a glutaminase inhibitor. Similarly, F16BP vaccine particles delivering TRP2 peptide
antigen along with poly(I:C) as adjuvant and PFK15, a glycolytic inhibitor, were able to reverse the growth of
subcutaneous YUMM1.1 tumors. The hypothesis of this proposal will be tested using the following specific
aims: Aim 1: Evaluate if F16BP particles induce antigen-specific long-term memory T cell responses in
immunocompetent mice in the presence of glycolytic inhibitor PFK15. Aim 2: Determine if PEGS particles can
induce antigen-specific long-term T cell responses in immunocompetent mice in the presence of glutaminase
inhibitor CB-839. Aim 3: Determine toxicity profile and maximum tolerable doses of vaccines. The results
obtained from these experiments will shed light on the effect of metabolic reprogramming on the efficacy of
vaccine therapy.
摘要
该提案的主要目标是开发基于生物材料的技术,
在存在全身递送的代谢抑制剂的情况下引流淋巴结中的DC和T细胞。的
该建议的假设是,由中心碳产生的基于聚合物生物材料的颗粒
代谢物(通过吞噬作用靶向DC)可以在存在下重新启动DC中的糖酵解/TCA循环。
代谢抑制剂,并且还将在免疫活性小鼠中诱导稳健的疫苗应答。值得注意的是,
已经从糖酵解和TCA循环中产生了中心碳代谢物的聚合物,这些聚合物能够
即使在代谢抑制剂存在下也能激活DC。此外,这些粒子能够拯救
代谢抑制,如通过上调细胞外酸化率(ECAR)和氧
消耗率(OCR)。递送TRP-2的体内PEGS颗粒制剂
肽(没有任何佐剂)能够防止皮下B16F10肿瘤在小鼠中的生长。
CB-839是一种转氨酶抑制剂。类似地,递送TRP2肽的F16BP疫苗颗粒
抗原沿着以poly(I:C)作为佐剂和PFK 15(一种糖酵解抑制剂)能够逆转
皮下YUMM1.1肿瘤。本提案的假设将使用以下具体指标进行检验
目的:目的1:评价F16 BP颗粒是否在小鼠中诱导抗原特异性长期记忆T细胞应答。
在糖酵解抑制剂PFK15的存在下,对免疫活性小鼠进行了细胞培养。目的2:确定PEGS颗粒是否可以
在存在转氨酶的情况下在免疫活性小鼠中诱导抗原特异性长期T细胞应答
抑制剂CB-839。目的3:确定疫苗的毒性特征和最大耐受剂量。结果
从这些实验中获得的结果将揭示代谢重编程对药物疗效的影响。
疫苗疗法
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Abhinav Acharya其他文献
Abhinav Acharya的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Abhinav Acharya', 18)}}的其他基金
Local immunometabolism modulating biomaterials for immunosuppressive applications
用于免疫抑制应用的局部免疫代谢调节生物材料
- 批准号:
10405419 - 财政年份:2021
- 资助金额:
$ 32.28万 - 项目类别:
Biomaterials-based metabolic rescue of dendritic cells for vaccine design
基于生物材料的树突状细胞代谢拯救用于疫苗设计
- 批准号:
10322658 - 财政年份:2021
- 资助金额:
$ 32.28万 - 项目类别:
Local immunometabolism modulating biomaterials for immunosuppressive applications
用于免疫抑制应用的局部免疫代谢调节生物材料
- 批准号:
10598113 - 财政年份:2021
- 资助金额:
$ 32.28万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 32.28万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 32.28万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 32.28万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 32.28万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 32.28万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 32.28万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 32.28万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 32.28万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 32.28万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 32.28万 - 项目类别: